8-K: CV Sciences Shareholders Affirm Board, Auditor, and Executive Pay at 2025 Annual Meeting

CV Sciences, Inc. announced the successful passage of all proposals at its 2025 Annual Meeting, including the re-election of three directors, ratification of its independent auditor, and approval of named executive officer compensation.

Summary

• CV Sciences, Inc. held its 2025 Annual Meeting virtually on June 2, 2025.
• A quorum was present with 100,682,501 shares, or approximately 54.6%, of the 184,263,663 outstanding common shares represented by proxy.
• Shareholders re-elected Dr. Jamie Corroon, Joseph Dowling, and Bill McCorkle to the Board of Directors, each to serve until the next Annual Meeting.
• Haskell & White LLP was ratified as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, with 92,535,025 votes for.
• The Company's named executive officer compensation was approved on a non-binding advisory basis, with 28,619,025 votes for.
• Shareholders approved, on a non-binding advisory basis, that the frequency of the advisory vote on named executive officer compensation should occur every two (2) years, receiving 27,373,437 votes for this option.

Sentiment

Score: 7

Explanation: The sentiment is generally positive as all management-backed proposals passed, indicating stable corporate governance and shareholder alignment, despite some votes showing notable abstentions or dissent.

Positives

• All three director nominees, Dr. Jamie Corroon, Joseph Dowling, and Bill McCorkle, were successfully re-elected to the Board.
• The selection of Haskell & White LLP as the independent registered public accounting firm for 2025 was ratified by a significant majority of votes.
• The Company's named executive officer compensation received advisory approval from shareholders.
• Shareholders provided clear guidance on the frequency of future executive compensation votes, opting for a biennial schedule.

Negatives

• Dr. Jamie Corroon's re-election saw a notable number of abstentions (16,914,582) and broker non-votes (64,709,241) compared to 'For' votes (17,035,995), indicating less overwhelming support than other directors.
• A substantial number of shares (64,709,241) were classified as 'Broker Non-Vote' for all director elections and the executive compensation frequency vote, indicating a significant portion of shares not voted on these matters.

Future Outlook

The company's stockholders approved that the advisory vote to approve named executive officer compensation will take place every two years, setting a future cadence for this governance item.

Management Comments

• Joseph Dowling, Chief Executive Officer, signed the report on behalf of CV Sciences, Inc.

Industry Context

This 8-K filing details routine corporate governance matters, specifically the outcomes of an annual shareholder meeting. It does not provide information related to broader industry trends, market conditions, or competitive landscape.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the election of directors and the approval of key corporate governance matters, including executive compensation and auditor selection.
• Management and Employees: The approval of named executive officer compensation directly impacts the company's leadership and potentially sets a precedent for broader compensation strategies.

Next Steps

• The elected directors will serve until the Company's next Annual Meeting of Stockholders.
• The advisory vote on named executive officer compensation will be held every two years, as approved by shareholders.

Key Dates

Keywords

CV Sciences, Annual Meeting, Shareholder Vote, Director Election, Auditor Ratification, Executive Compensation, Corporate Governance, Proxy Statement, 8-K Filing